What oral or injectable medication can be prescribed for dyshidrotic eczema affecting the interdigitated areas of the hands?

Systemic Treatment for Dyshidrotic Hand Eczema

For dyshidrotic eczema affecting the hands between fingers, dupilumab 600 mg subcutaneous loading dose followed by 300 mg every 2 weeks is the strongest evidence-based systemic treatment, with dramatic improvement typically seen within days to weeks. 1, 2

First-Line Systemic Options

Dupilumab (Strongest Evidence)

• Loading dose: 600 mg subcutaneous injection
• Maintenance: 300 mg subcutaneous every 2 weeks
• Onset: Improvement can begin within 3 days, with complete clearance by 6 weeks in severe cases 1
• Evidence: Multiple case reports and series demonstrate excellent response in recalcitrant dyshidrotic eczema 1, 2
• Safety profile: Well-tolerated; main adverse effect is conjunctivitis (manageable with artificial tears in most cases) 3
• Advantage: FDA-approved for atopic dermatitis, which includes dyshidrotic eczema as part of the spectrum 4

JAK Inhibitors (Strong Alternative)

Baricitinib is the best-studied oral option:

• Dose: 2-4 mg daily (start at 4 mg for faster control, then reduce to 2 mg for maintenance)
• Onset: Moderate to significant improvement within 2-8 weeks 5
• Evidence: Nine cases showed consistent improvement in chronic hand and foot eczema 5
• Monitoring required: Baseline and periodic CBC, lipids, liver function 6
• Contraindications: Age >65, cardiovascular disease history, thromboembolism risk, active malignancy 6

Tralokinumab (IL-13 inhibitor):

• Dose: 600 mg subcutaneous loading, then 300 mg every 2 weeks
• Evidence: First reported successful case of dyshidrotic eczema treatment 4
• Advantage: Similar mechanism to dupilumab with potentially lower conjunctivitis rates

Second-Line Options (When First-Line Fails)

Cyclosporine

• Dose: 3-5 mg/kg/day divided twice daily 3
• Duration: Limited to 1 year maximum 3
• Monitoring: Baseline and monthly blood pressure, creatinine, lipids
• Caution: Drug interactions and comorbidities (hypertension, renal disease) make this inappropriate for many patients 3

Mycophenolate Mofetil

• Dose: 1-3 g daily in divided doses (or mycophenolic acid 720-2160 mg daily) 3
• Monitoring: Baseline and periodic CBC, liver function
• Evidence: Moderate certainty for atopic dermatitis spectrum disorders 3

Methotrexate

• Dose: 7.5-25 mg weekly with folic acid supplementation 3
• Monitoring: Baseline hepatitis panel, CBC, liver function; repeat CBC and liver function every 4-12 weeks
• Contraindications: Pregnancy, liver disease, significant alcohol use

Practical Algorithm

Step 1: If patient has failed topical corticosteroids and is seeking rapid relief:

• Choose dupilumab (fastest onset, best safety profile, no lab monitoring required)

Step 2: If dupilumab unavailable or patient prefers oral medication:

• Age <65, no cardiovascular/thrombosis history: Baricitinib 4 mg daily
• Age >65 or cardiovascular concerns: Consider mycophenolate mofetil instead

Step 3: If first-line fails after 12-16 weeks:

• Switch to alternative first-line agent (dupilumab ↔ JAK inhibitor)
• Or add short-term cyclosporine as bridge therapy

Step 4: For refractory cases:

• Consider methotrexate or mycophenolate mofetil
• Refer to dermatology for phototherapy consideration 7

Critical Monitoring Points

For Dupilumab/Tralokinumab:

• No baseline labs required 3
• Monitor for conjunctivitis (most common adverse effect)
• Refer to ophthalmology if conjunctivitis is severe or persistent 3

For JAK Inhibitors:

• Baseline: CBC, lipids, liver function, tuberculosis screening 6
• Periodic: Repeat labs every 3 months initially, then every 6 months if stable
• Assess cardiovascular and thrombosis risk factors before initiating 6

For Traditional Immunosuppressants:

• More intensive monitoring required per individual drug protocols 3

Common Pitfalls to Avoid

1. Don't use systemic corticosteroids long-term - Only for acute flares as bridge therapy 7
2. Don't continue cyclosporine beyond 1 year - Nephrotoxicity risk increases 3
3. Don't forget vaccination status - Update before starting JAK inhibitors or other immunosuppressants 6
4. Don't ignore hyperhidrosis - If coexistent, consider adding oxybutynin (can dramatically improve dyshidrotic eczema) 8
5. Don't overlook contact allergens - Consider patch testing if recalcitrant, though less commonly positive in dyshidrotic pattern (43% vs 52% in other hand eczema) 9

The evidence strongly favors dupilumab as first-line systemic therapy given its rapid onset, excellent safety profile, and lack of monitoring requirements, making it the most practical choice for most patients with dyshidrotic hand eczema requiring systemic treatment.